Supplementary Table 1: PICO framework table.

Outcomes of interest using PICO framework and data points of interest

	Inclusion criteria:
Donulation	- adult population with cancer,
	- all solid organ tumour sites.
Population	
	Exclusion criteria:
	- animal studies.
	inclusion criteria:
	- trials that included the use of a VEGF-inhibitors (VEGFI), and/or in combination
	with immune checkpoint inhibitors (ICIs) class of drugs for the treatment of
	cancer,
	- VEGFI with or without ICI used as either control arm or intervention arm of
	study,
	- phase II, III and IV trials,
	- randomised studies,
	- published in English language,
Intervention	- completed enrolment,
	The specific intervention exclusion criteria are listed below:
	- single dosing,
	- sequential therapy rather than concurrent therapy,
	- population of treatment group of <20 patients,
	-non-randomised trials
	- meta-analysis,
	- review articles or commentaries,
	- subsequent therapy analysis,

	- cost-effective analysis,				
	- published abstracts,				
	- patient reported outcomes,				
	- subgroup analysis,				
	- duplications,				
	- retrospective analysis.				
	Trials that have incomplete protocol and text will be included in the results as part				
	of our objective is to identify the representation of patients with kidney disease in				
	trial data.				
Comparison	Not applicable				
	We will collect the following data points from the extracted articles regarding the				
	exclusion and representation of patients with kidney disease:				
	1. Are patients with any form of kidney disease excluded in design/eligibility				
	criteria?				
	Was marker of kidney function used as exclusion criteria				
	 Definition(s) of kidney function used 				
	- Cut off value(s)				
	- Were alternative measure of GFR allowed (MDRD, CKD-EPI, urine				
Outcome	creatinine collection, measured)?				
	2. Were patients with proteinuria excluded from the trial?				
	 Method(s) used as proteinuria screen 				
	o Urinalysis				
	o Urine PCR/ACR				
	o 24 hour urine collection				
	 Cut off value for exclusion 				
	3. Were patients with kidney/solid organ transplants excluded?				

- 4. Were patients on regular immunosuppression excluded?
- 5. Did patients have nephrectomy?
- 6. Did the trial analyse effect of benign kidney disease on primary outcome?
- 7. Is the kidney function of trial population available in baseline characteristics or supplementary materials?

We plan to collect similar exclusions of patients with cardiovascular disease:

- 1. Were patients excluded with cardiovascular disease?
- 2. Were patients excluded with the following diagnosis:
- Hypertension
- Coronary artery disease (CAD)
- Heart failure
- Cardiomyopathy
- Arrhythmia
- Valvular disease
- Thromboembolic disease
- Cerebrovascular disease
- Abnormal ECG
- Myocarditis
- Pericarditis
- Vasculitis
- 3. Are the diagnosis of cardiovascular disease of trial population available in baseline characteristics or supplementary materials?
- 4. Are cardiovascular adverse events reported in the published clinical trial or supplement?

We will also collect the following information about the trial characteristics to analysis if this had an influence on the trial design or patient enrolment:

- 1. Is the trial ID number identifiable?
- 2. Is the trial name identifiable?
- 3. What is the trial design?
- 4. Was this a randomised control design?
- 5. Was this intervention or control?
- 6. Was there an active comparator?
- 7. Trial year published
- 8. Trial population size
- 9. Funding source
- 10. Cancer diagnosis
- 11. Is trial protocol available?
- 12. How were adverse events defined and were they adjudicated?
- 13. Is there a clear safety follow up period specified in the protocol?
- 14. Is data collected on adverse events of special interest?
- 15. Are adverse events of special interest defined in the protocol?

Supplementary Table 2: List of VEGF inhibitors and immune checkpoint inhibitors & systematic review search terms

VEGF inhibitors					
Tyrosine kinase Inhibitor					
Apatinib	Pazopanib				
Axitinib	Regorafenib				
Brivanib alaninate	Sorafenib				
Cabozantinib	Sunitinib				
Cediranib	Tivozinib				
Dovitinib	Vandetanib				
Lenvatinib	Vatalanib				
Nintedanib					
Monoclonal antibodies					
Bevacizumab	Ramucirumab				
VEGF-Tra	p mediators				
Aflibercept					
Immune check	point inhibitors				
PI)-1				
Pembrolizumab	Cemiplimab				
Nivolumab					
PD-L1					
Atezolizumab	Durvalumab				
Avelumab					
CTLA-4					
Ipilimumab	Tremelimumab				
Search Terms					
(("Phase II" OR "Phase 2" OR "Phase III" OR "Phase	hase 3" OR "Phase IV" OR "Phase 4") AND				
(Ipilimumab OR Tremelimumab OR Atezolizumab OR Avelumab OR Durvalumab OR					
Pembrolizumab OR Nivolumab OR Cemiplimab) AND					
(Apatinib OR Axitinib OR Bevacizumab OR Aflibercept OR 'Brivanib alaninate' OR Cabozantinib					
OR Cediranib OR Dovitinib OR Ramucirumab OR Lenvatinib OR Nintedanib OR Pazopanib OR					
Regorafenib OR Sorafenib OR Sunitinib OR Tivozanib OR Vandetanib OR Vatalanib))					


Abbreviations: VEGF, Vascular endothelial growth factor; PD-1, Programmed cell death protein-1;

PD-L1, Programmed death ligand-1; CTLA-4, Cytotoxic T-lymphocyte protein-4

Supplementary Table 3. Summary of trial characteristics and exclusions

	Number of trials	Number of
	n (%)	patients n (%)
Total (randomized controlled trials)	17	10313
Tumour t	ype	
Renal	6 (35)	4687 (45)
Gynaecological (endometrial, ovarian, cervical)	4 (24)	2827 (27)
Lung	2 (12)	1752 (17)
Liver	1 (6)	501 (5)
Bowel	3 (18)	466 (5)
Brain	1 (6)	80 (1)
Trial Pha	ase	
III	12 (71)	9687 (94)
II	5 (29)	626 (6)
ICI and VEGFi	combination	
Atezolizumab & bevacizumab	6 (35)	4357 (42)
Pembrolizumab & Lenvatinib	2 (12)	1896 (18)
Pembrolizumab & bevacizumab	3 (18)	1004 (10)
Avelumab & axitinib	1 (6)	886 (9)
Pembrolizumab & axitinib	1 (6)	861 (8)
Nivolumab & cabozantinib	2 (12)	733 (7)
Nivolumab & bevacizumab	1 (6)	550 (5)
Avelumab & bevacizumab	1 (6)	26 (0.3)

Supplementary Figure 1: Percentage of participants in ICI/VEGFi combination trials subject to cardiovascular exclusion criteria



Supplementary Figure 2: Percentage of participants in ICI/VEGFi combination therapy trials for whom cardiovascular adverse events were reported

